On June 17, 2025, Citigroup analyst Geoff Meacham initiated coverage of Novavax (NVAX, Financial) with a 'Sell' rating. This marks the start of Citigroup's analytic evaluation of the stock, providing investors with a new perspective on the company's financial outlook.
The current price target for Novavax (NVAX, Financial) has been announced at $6.00 USD. This target reflects the firm's valuation assessment of the stock as it stands in today's market conditions.
Novavax (NVAX, Financial) is under the spotlight as Citigroup joins other financial entities in analyzing its market performance. The 'Sell' rating suggests caution, as it indicates the analyst's perception that the stock may underperform in comparison to its market peers.
Investors in Novavax (NVAX, Financial) should take note of this latest analyst rating from Citigroup as it can influence trading strategies and financial decisions. The rating and price target offer a clear signal of how Citigroup views the company's potential trajectory in the financial landscape.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Novavax Inc (NVAX, Financial) is $16.67 with a high estimate of $25.00 and a low estimate of $9.00. The average target implies an upside of 137.08% from the current price of $7.03. More detailed estimate data can be found on the Novavax Inc (NVAX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Novavax Inc's (NVAX, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Novavax Inc (NVAX, Financial) in one year is $6.35, suggesting a downside of 9.67% from the current price of $7.03. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Novavax Inc (NVAX) Summary page.
